Silodosin and its potential for treating premature ejaculation: a preliminary report

Area of Science:

• Urology
• Pharmacology
• Sexual Medicine

Background:

• Premature ejaculation (PE) is a prevalent sexual dysfunction.
• Silodosin is a highly selective α1A-adrenoceptor antagonist known for treating lower urinary tract symptoms.
• Silodosin has demonstrated a higher incidence of ejaculation suppression compared to other α1-adrenoceptor antagonists.

Purpose of the Study:

• To evaluate the feasibility of off-label silodosin as a novel treatment for premature ejaculation.
• To assess the efficacy of silodosin in improving intravaginal ejaculatory latency time (IELT) and patient-reported outcomes in PE.

Main Methods:

• An open-label study involving eight patients diagnosed with premature ejaculation.
• Silodosin (4 mg) was administered 2 hours prior to sexual intercourse.
• Key outcome measures included IELT, Premature Ejaculation Profile (PEP), Clinical Global Impression (CGI), and adverse events.

Main Results:

• Silodosin significantly prolonged IELT from a mean of 3.4 minutes to 10.1 minutes (P = 0.003).
• All patients reported subjective improvement in their PE symptoms (much better or slightly better) on the CGI scale.
• Significant improvements were observed in the PEP, although side effects like anejaculation (25%), reduced semen volume (37.5%), and discomfort during orgasm (87.5%) were noted but not considered major concerns.

Conclusions:

• Off-label silodosin demonstrates potential as a new therapeutic option for premature ejaculation.
• The observed ejaculation suppression and prolonged latency suggest a viable mechanism for PE treatment.
• Further placebo-controlled trials are warranted to confirm the clinical utility and safety of silodosin for premature ejaculation.